AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27978912 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment using periodontal endoscope
Number of subjects: 11
Study 27978912 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment method (control group)
Number of subjects: 11
Study 25027286 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 18
Study 25027286 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 18
Study 25027286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22739747 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy (AIT)
Number of subjects: 50
Study 20697905 — intervention group
Group type: EXPERIMENTAL
Intervention: Water environment
Number of subjects: 9
Study 20697905 — intervention group
Group type: COMPARATOR
Intervention: Dry land environment
Number of subjects: 9
Study 19001830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 101
Study 19001830 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 101
Study 15926439 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 24
Study 15926439 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 12011683 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with cytokine adjuvants, peeling of the internal limiting membrane, vital staining with indocyanine green dye, variations in postoperative face-down positioning
Number of subjects: 0
Study 9642895 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive therapy
Number of subjects: 144
Study 9642895 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 144
Study 9642895 — intervention group
Group type: COMPARATOR
Intervention: Both forms of therapy
Number of subjects: 144
Study 8124800 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 288
Study 2811412 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial pH adjusted in a randomized order (high to low or low to high) in group I patients during hypothermic cardiopulmonary bypass.
Number of subjects: 50
Study 2811412 — intervention group
Group type: COMPARATOR
Intervention: Constant arterial pH during stable hypothermia in group II patients.
Number of subjects: 50
Study 1217691 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylates (Colfarit)
Number of subjects: 50
Study 1217691 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic medications (Control)
Number of subjects: 50
Study 31822203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 49
Study 30892806 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin (target serum concentration 8-18 ng/mL)
Number of subjects: 2190
Study 30892806 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 2190
Study 28224950 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection-site splinting (experimental group)
Number of subjects: 60
Study 28224950 — intervention group
Group type: COMPARATOR
Intervention: No injection-site splinting (control group)
Number of subjects: 60
Study 26027223 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin 1.5% (succinate‐containing infusion solution)
Number of subjects: 87
Study 26027223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 87
Study 23088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval strategy
Number of subjects: 0
Study 23088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention strategy
Number of subjects: 0
Study 23088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy confidence and perceived strategy difficulty
Number of subjects: 0
Study 23088195 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived speed of responses
Number of subjects: 0
Study 21422859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g administered 30-60 minutes before skin incision
Number of subjects: 29
Study 20039532 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational Internet self-help tool
Number of subjects: 67
Study 20039532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 17024647 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL group (living high-training low)
Number of subjects: 16
Study 17024647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 17024647 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTL group
Number of subjects: 16
Study 15127162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thêta-Cream
Number of subjects: 20
Study 15127162 — intervention group
Group type: COMPARATOR
Intervention: Bepanthol lotion
Number of subjects: 20
Study 11388099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial undersensing < 5% (group 1)
Number of subjects: 21
Study 11388099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial undersensing 5%-10% (group 2)
Number of subjects: 21
Study 11388099 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial undersensing > 10% (group 3)
Number of subjects: 21
Study 9915106 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 7
Study 9915106 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 7
Study 9915106 — intervention group
Group type: COMPARATOR
Intervention: Basal (no drug administration)
Number of subjects: 7
Study 7708266 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R measurement in patients undergoing kidney graft
Number of subjects: 136
Study 7708266 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R measurement in longstanding recipients
Number of subjects: 136
Study 7708266 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R measurement during graft rejection
Number of subjects: 136
Study 7708266 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-R/SCr levels
Number of subjects: 136
Study 7708266 — intervention group
Group type: EXPERIMENTAL
Intervention: sIl2-R measurement
Number of subjects: 136
Study 30613020 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (loading dose of 0.6 mg·kg‐1·h‐1 followed by maintenance dose of 3 mg·kg‐1·h‐1)
Number of subjects: 60
Study 30613020 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 60
Study 27745552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic follow-up at 2 weeks
Number of subjects: 731
Study 27745552 — intervention group
Group type: COMPARATOR
Intervention: Home-assessment at 2 weeks
Number of subjects: 731
Study 27745552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic follow-up at 3 months
Number of subjects: 731
Study 27745552 — intervention group
Group type: COMPARATOR
Intervention: Home-assessment at 3 months
Number of subjects: 731
Study 24785921 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional brackets
Number of subjects: 100
Study 24785921 — intervention group
Group type: EXPERIMENTAL
Intervention: Active self‐ligating brackets
Number of subjects: 100
Study 24785921 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive self‐ligating brackets
Number of subjects: 100
Study 24785921 — intervention group
Group type: EXPERIMENTAL
Intervention: All bracket types
Number of subjects: 100
Study 22820601 — intervention group
Group type: EXPERIMENTAL
Intervention: RhTPO (1.0 µg/kg) administered subcutaneously daily for 7 days starting 3 days before the second chemotherapy cycle (Group A)
Number of subjects: 24
Study 22820601 — intervention group
Group type: EXPERIMENTAL
Intervention: RhTPO (1.0 µg/kg) administered daily for 7 days starting 6-24 hours after the second chemotherapy cycle (Group B)
Number of subjects: 24
Study 22820601 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no RhTPO administered during the first chemotherapy cycle)
Number of subjects: 24
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐IgG positive at the first trimester
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐IgG seroconversion
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV‐IgM seroconversion
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CMV‐IgG and CMV‐IgM positive
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of primary CMV infection during pregnancy
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated incidence of congenital infection
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital CMV infection
Number of subjects: 339
Study 19919637 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological sequelae in congenitally infected infants
Number of subjects: 339
Study 18505112 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (group B)
Number of subjects: 28
Study 18505112 — intervention group
Group type: COMPARATOR
Intervention: Without non-invasive ventilation (group A)
Number of subjects: 28
Study 18505112 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 28
Study 16595242 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic chromopertubation with lipiodol
Number of subjects: 88
Study 16595242 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 88
Study 12930046 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐administered Client Perceptions of Coordination Questionnaire
Number of subjects: 1193
Study 12930046 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain syndromes
Number of subjects: 1193
Study 10627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured examination schedule for the diagnosis and classification of musculoskeletal disorders of the upper limb
Number of subjects: 88
Study 9177592 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (6-week supervised program)
Number of subjects: 33
Study 9177592 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education program (instruction and demonstration of heat, cold, massage, relaxation, distraction)
Number of subjects: 33
Study 9177592 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study 8241701 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 therapy
Number of subjects: 120
Study 8241701 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without coenzyme Q10 therapy)
Number of subjects: 120
Study 8241701 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 120
Study 8241701 — intervention group
Group type: COMPARATOR
Intervention: Patients with asymptomatic mitral valve prolapse
Number of subjects: 120
Study 4089312 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (3 X 250 mg/day)
Number of subjects: 14
Study 31100534 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP (200 μg)
Number of subjects: 8
Study 31100534 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2 (800 μg)
Number of subjects: 8
Study 31100534 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2 (800 pmol/kg/min) + GLP-2 (800 μg)
Number of subjects: 8
Study 31100534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30129904 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 40
Study 30129904 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy
Number of subjects: 40
Study 26769876 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 100
Study 26769876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26769876 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal (all participants)
Number of subjects: 100
Study 25383369 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography-guided botulinum toxin injection
Number of subjects: 30
Study 25383369 — intervention group
Group type: COMPARATOR
Intervention: Fiberscopy-guided botulinum toxin injection
Number of subjects: 30
Study 22490651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (various doses)
Number of subjects: 101
Study 22490651 — intervention group
Group type: COMPARATOR
Intervention: Control (no mifepristone)
Number of subjects: 101
Study 22490651 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (high dose)
Number of subjects: 101
Study 20506004 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 0
Study 20506004 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs
Number of subjects: 0
Study 17906182 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-supplemented diet (mean 35 grams daily, 12% total energy)
Number of subjects: 40
Study 17906182 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 40
Study 16135576 — intervention group
Group type: COMPARATOR
Intervention: 28-day cycle (standard regimen)
Number of subjects: 561
Study 16135576 — intervention group
Group type: EXPERIMENTAL
Intervention: 49-day cycle (every other month)
Number of subjects: 561
Study 16135576 — intervention group
Group type: EXPERIMENTAL
Intervention: 91-day cycle (every third month)
Number of subjects: 561
Study 16135576 — intervention group
Group type: EXPERIMENTAL
Intervention: 364-day cycle (continuous)
Number of subjects: 561
Study 12188483 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of steroid (20 mg of triamcinolone with lignocaine)
Number of subjects: 0
Study 12188483 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock-wave therapy (2000 shock waves in three sessions at weekly intervals)
Number of subjects: 0
Study 10457271 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily for 1 year)
Number of subjects: 103
Study 10457271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8543362 — intervention group
Group type: EXPERIMENTAL
Intervention: Broka's index
Number of subjects: 0
Study 8543362 — intervention group
Group type: EXPERIMENTAL
Intervention: Broka's index, BMI and weight for height (%)
Number of subjects: 0
Study 2110559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 300 mg/day
Number of subjects: 224
Study 2110559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 121639 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (Fasigyn; Pfizer)
Number of subjects: 50
Study 121639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31970791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical education program based on Watson's human caring theory
Number of subjects: 106
Study 31298823 — intervention group
Group type: EXPERIMENTAL
Intervention: e-coaching and standard of care (SOC)
Number of subjects: 402
Study 31298823 — intervention group
Group type: COMPARATOR
Intervention: standard of care (SOC)
Number of subjects: 402
Study 31298823 — intervention group
Group type: EXPERIMENTAL
Intervention: e-coaching and SOC
Number of subjects: 402
Study 28650224 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured organizational change intervention with external coaching based on the NIATx process improvement model
Number of subjects: 0
Study 28650224 — intervention group
Group type: COMPARATOR
Intervention: Control condition (baseline training about best practices in HIV testing)
Number of subjects: 0
Study 25884452 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits (up to three visits)
Number of subjects: 278
Study 25884452 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 278
Study 24009027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 2293
Study 24009027 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores 1 and 2
Number of subjects: 2293
Study 21311196 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized computerized cognitive training
Number of subjects: 155
Study 21311196 — intervention group
Group type: COMPARATOR
Intervention: Computer games
Number of subjects: 155
Study 19284933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone (10 mg to 40 mg once a day for 8 weeks)
Number of subjects: 410
Study 19284933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 17591131 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia
Number of subjects: 874
Study 15080853 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (direct mail)
Number of subjects: 113
Study 15080853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 113
Study 11699379 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupressure
Number of subjects: 97
Study 11699379 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 97
Study 9306077 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20mg/day for 14 weeks)
Number of subjects: 75
Study 9306077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8392261 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids treatment
Number of subjects: 0
Study 8392261 — intervention group
Group type: COMPARATOR
Intervention: Symptom-free controls
Number of subjects: 0
Study 3595572 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (neurolept or halothane)
Number of subjects: 24
Study 3595572 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 24
Study 3595572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 24
Study 31704382 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 535
Study 31704382 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 535
Study 28623089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 0.5% (12.6mg) with 15μg fentanyl and 75μg morphine
Number of subjects: 0
Study 28623089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 0.5% (6.0mg) with 15μg fentanyl and 75μg morphine
Number of subjects: 0
Study 28623089 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of bupivacaine
Number of subjects: 0
Study 24689952 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention (theory-based instructional leaflets)
Number of subjects: 155
Study 24689952 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 155
Study 26118157 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate + Amodiaquine (AA group)
Number of subjects: 252
Study 26118157 — intervention group
Group type: COMPARATOR
Intervention: Artemether + Lumefantrine (AL group)
Number of subjects: 252
Study 21806251 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 μm CO2-laser irradiation (Pulse System Inc, Los Alamos, New Mexico), pulse duration 20 μs, pulse repetition rate 20 Hz, average fluence 4.1 ± 0.3 J/cm², 20 laser pulses per spot
Number of subjects: 24
Study 21806251 — intervention group
Group type: COMPARATOR
Intervention: Control (nonirradiated area)
Number of subjects: 24
Study 19459477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo 23 vaccine
Number of subjects: 63
Study 19459477 — intervention group
Group type: COMPARATOR
Intervention: Control group (children born from HIV-negative women)
Number of subjects: 63
Study 16896837 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bond with methylene blue
Number of subjects: 40
Study 16896837 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bond with silver nitrate
Number of subjects: 40
Study 16896837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with methylene blue
Number of subjects: 40
Study 16896837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond with silver nitrate
Number of subjects: 40
Study 16896837 — intervention group
Group type: COMPARATOR
Intervention: Single bond and Clearfil SE Bond (both with methylene blue)
Number of subjects: 40
Study 16896837 — intervention group
Group type: COMPARATOR
Intervention: Single bond and Clearfil SE Bond (both with silver nitrate)
Number of subjects: 40
Study 15566506 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b plus ribavirin (100 microg once weekly and 800 mg/day orally)
Number of subjects: 96
Study 15566506 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha-2b plus ribavirin (3 million units thrice weekly and 800 mg/day)
Number of subjects: 96
Study 11137745 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ECP measurement
Number of subjects: 10
Study 11137745 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil count
Number of subjects: 10
Study 11137745 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 10
Study 11137745 — intervention group
Group type: COMPARATOR
Intervention: Reference group (healthy subjects)
Number of subjects: 10
Study 9117523 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 8
Study 9117523 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 7930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sowdah type onchocerciasis
Number of subjects: 92
Study 7930741 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized form of onchocerciasis
Number of subjects: 92
Study 7930741 — intervention group
Group type: COMPARATOR
Intervention: Endemic normal persons
Number of subjects: 92
Study 7930741 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed persons
Number of subjects: 92
Study 3336176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to forearm
Number of subjects: 30
Study 3336176 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin applied to face
Number of subjects: 30
Study 3336176 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied to forearm
Number of subjects: 30
Study 3336176 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied to face
Number of subjects: 30